RESVERA

Resvera is a clinical-stage biotechnology company focused on developing novel therapies for respiratory viral infections, with a primary emphasis on respiratory syncytial virus (RSV). The company's lead candidate is an oral small molecule inhibitor designed to block the fusion process of the virus, potentially providing a potent treatment option for both pediatric and elderly populations. Resvera aims to address the significant unmet medical need in RSV management, where current treatment options are limited. By targeting the viral fusion protein, the company's technology seeks to reduce viral load and improve clinical outcomes in infected patients.